Treatment of Progressive Stage IV, Relapsed, and Recurrent Non-Small Cell Lung Cancer

For information about the treatments listed below, see the Treatment Option Overview section.

Treatment of progressive stage IV, relapsed, and recurrent non-small cell lung cancer may include the following:

• Chemotherapy.
• Targeted therapy with an EGFR tyrosine kinase inhibitor, such as erlotinib, gefitinib, afatinib, osimertinib, or amivantamab.
• Targeted therapy with an ALK inhibitor, such as crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib.
• Targeted therapy with a BRAF inhibitor or MEK inhibitor, such as dabrafenib or trametinib.
• Targeted therapy with crizotinib and entrectinib to stop proteins from being made by the ALK and ROS1 genes.
• Targeted therapy with a NTRK inhibitor, such as larotrectinib or entrectinib.
• Targeted therapy with a RET inhibitor, such as selpercatinib or pralsetinib.
• Targeted therapy with a MET inhibitor, such as tepotinib or capmatinib.
• Targeted therapy with a KRAS G12C inhibitor, such as sotorasib or adagrasib.
• Targeted therapy with trastuzumab deruxtecan for HER2-positive cancers.
• Immunotherapy with an immune checkpoint inhibitor, such as nivolumab, pembrolizumab, or atezolizumab.
• Targeted therapy with an mTOR inhibitor, such as everolimus.
• A clinical trial of new drugs and combinations of treatments.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.